February 26, 2024
GLP-1s are drugs proven to treat diabetes. But with high costs, increased use for other purposes and clinical uncertainty, GLP-1s are not without controversy. This brief underscores the history of these medications and makes policy recommendations to ensure patients are receiving the right drugs at the right time.
New from ACHP:
- ACHP Statement on MAHA Commission
- ACHP Statement on Confirmation of Robert F. Kennedy Jr. as HHS Secretary
- ACHP Letter to CMS on CY 2026 MA and Part D Rate Notice
- ACHP Letter to CMS on Proposed CY 2026 Policy and Technical Changes
- ACHP Letter to National Association of Medicaid Directors
- ACHP Statement on 2027 Medicare Drug Negotiations